Biochemical Pharmacology

Our medical research library holds 6 studies published in Biochemical Pharmacology (1981–2023). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 4 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 1 study PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

About the journal

• Publisher: Elsevier Science
• Published: 1958 to the present, England
• Language: English
• ISSN: 0006-2952 (print), 1873-2968 (electronic)
• Its record in the NLM Catalog

2020s

• Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma. V. Coccè, M. Bonelli, S. La Monica, et al. 2023;214:115678. PubMed · Publisher

  Abstract

  Malignant pleural mesothelioma is an asbestos-related tumor originating in mesothelial cells of the pleura that poorly responds to chemotherapeutic approaches. Adult mesenchymal stromal cells derived either from bone marrow or from adipose tissue may be considered a good model for cell-based therapy, a treatment which has experienced significant interest in recent years. The present study confirms that Paclitaxel is effective on mesothelioma cell proliferation in 2D and 3D in vitro cultures, and that 80,000 mesenchymal stromal cells loaded with Paclitaxel inhibit tumor growth at a higher extent than Paclitaxel alone. An in vivo approach to treat in situ mesothelioma xenografts using a minimal amount of 106 mesenchymal stromal cells loaded with Paclitaxel showed the same efficacy of a systemic administration of 10 mg/kg of Paclitaxel. These data strongly support drug delivery system by mesenchymal stromal cells as a useful approach against many solid tumors. We look with interest at the favourable opinion recently expressed by the Italian Drug Agency on the procedure for the preparation of mesenchymal stromal cells loaded with Paclitaxel in large-scale bioreactor systems and their storage until clinical use. This new Advanced Medicinal Therapy Product, already approved for a Phase I clinical trial on mesothelioma patients, could pave the way for mesenchymal stromal cells use as drug delivery system on other solid tumors for adjuvant therapy associated with surgery and radiotherapy.

  Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

2010s

• New therapeutic strategies for malignant pleural mesothelioma. M.A. Bonelli, C. Fumarola, S. La Monica, et al. 2017;123:8-18. Review PubMed · Publisher

  Abstract

  Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which most patients are diagnosed and the intrinsic chemo-resistance of the tumor. The recommended systemic therapy for MPM is cisplatin/pemetrexed regimen with a mean overall survival of about 12months and a median progression free survival of less than 6months. Considering that the incidence of this tumor is expected to increase in the next decade and that its prognosis is poor, novel therapeutic approaches are urgently needed. For some tumors, such as lung cancer and breast cancer, druggable oncogenic alterations have been identified and targeted therapy is an important option for these patients. For MPM, clinical guidelines do not recommend biological targeted therapy, mainly because of poor target definition or inappropriate trial design. Further studies are required for a full comprehension of the molecular pathogenesis of MPM and for the development of new target agents. This review updates pre-clinical and clinical data on the efficacy of targeted therapy and immune checkpoint inhibition in the treatment of mesothelioma. Finally, future perspectives in this deadly disease are also discussed.

  Copyright © 2016 Elsevier Inc. All rights reserved.

• Pro-oxidant activity of polyphenols and its implication on cancer chemoprevention and chemotherapy. A.J. León-González, C. Auger, V.B. Schini-Kerth. 2015;98(3):371-80. PubMed · Publisher

  Abstract

  Reactive oxygen species (ROS) play a major role in carcinogenesis: pro-oxidant agents like tobacco smoke, asbestos or N-nitrosamines, are known as mutagenic and carcinogenic, and cancer cells show increased levels of ROS and redox deregulation. However, pro-oxidant molecules can also act as selective cytotoxic agents against cancer cells by achieving toxic levels of ROS. Although polyphenols are well-known as potent antioxidants, a pro-oxidant effect has been associated with their pro-apoptotic effect in various types of tumor cells. The aim of the present review is to present the main evidences of the pro-oxidant-related cytotoxic activity of naturally occurring polyphenols and their underlying mechanisms.

  Copyright © 2015 Elsevier Inc. All rights reserved.

1990s

• Iron mobilization from crocidolite as enhancer of collagen content in rat lung fibroblasts. C. Gardi, P. Calzoni, M. Ferrali, et al. 1997;53(11):1659-65. PubMed · Publisher

  Abstract

  Asbestos exposure causes pulmonary fibrosis by mechanisms that remain uncertain. There is increasing evidence that iron from asbestos is responsible for many of its effects. In this paper, we investigated the effect of iron mobilized from crocidolite asbestos on collagen content in rat lung fibroblast cultures under serum-free conditions. Crocidolite (2, 4, 6 microg/cm2 well) increased collagen content in a dose-dependent manner (+42 +/- 8, +92 +/- 10, and +129 +/- 13% vs controls). This effect was specific for collagen, since it did not alter total protein content and was inhibited by the iron chelator deferoxamine (DFO). Preincubation of crocidolite with citrate (1 mM) for 48 hr resulted in iron mobilization (51 microM) and increased collagen production (>3-fold) in treated cells. These effects occurred without the intervention of serum factors. The absence of cell damage, proliferation or lipid peroxidation leads to the supposition that iron from crocidolite per se may act as a profibrogenic agent. Although the in vivo participation of other cells and factors cannot be excluded, we conclude that iron released from crocidolite plays a role in collagen increase occurring during asbestosis.

1980s

• The price of progress or Pandora's purse. E. Bresnick. 1983;32(8):1331-6. Review PubMed · Publisher

• Pulmonary metabolism of benzo(a) pyrene : effect of asbestos. C. Kandaswami, P.J. O'Brien. 1981;30(7):811-4. PubMed · Publisher

  Summary

  This preliminary communication examined whether asbestos affects the activity of aryl hydrocarbon hydroxylase, the enzyme system that metabolizes the carcinogen benzo(a)pyrene, in rat lung. The authors noted that asbestos and polycyclic aromatic hydrocarbons in cigarette smoke appear to act synergistically in causing lung cancer. Male Sprague-Dawley rats (200-250 g) were pretreated with 3-methylcholanthrene (40 mg/kg i.p. daily for 4 days), and lung microsomal fractions were isolated. Standard asbestos samples were supplied by the International Union Against Cancer. In one procedure, microsomes were preincubated with 2 mg of asbestos for 1 hour at 37°C. In another, benzo(a)pyrene was preincubated with a small amount of asbestos (50 µl of a 0.5 mg/ml suspension) for 10 minutes before microsomes were added. Enzyme activity was measured by fluorescence of phenolic products. With microsomal preincubation, activity relative to the asbestos-free control was 34% with crocidolite, 46% with Canadian chrysotile B, 38% with amosite and 40% with anthophyllite (averages of 3 experiments). Pretreating benzo(a)pyrene with asbestos also lowered activity, to 58% with crocidolite and 64% with chrysotile. The metal chelator EDTA did not affect inhibition by asbestos, although it protected the enzyme against copper. The authors concluded that asbestos could prevent benzo(a)pyrene from being metabolized in lung tissue. This might slow its clearance and prolong its retention. The inhibition did not appear to be due to trace metals associated with asbestos.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

Browse every journal in the library or the library by type of article, or return to medical research.